In a formal statement released from its Haikou headquarters, the company confirmed that it remains unaware of any material nonpublic information that might explain the recent surge in market activity. China Pharma, which specializes in cardiovascular, infectious, and digestive disease treatments, maintains that its internal operations have not deviated from routine business practices. While the exchange routinely monitors for such anomalies, the company’s leadership emphasized that no pending business developments or hidden events could account for the trading patterns observed over the three-day period. China Pharma operates eight GMP-certified production lines and a nationwide distribution network, yet it continues to operate under its standard policy of declining comment on specific market movements unless required by regulatory oversight.
In section Releases
China Pharma Denies Knowledge of Causes Behind Stock Price Volatility
The NYSE American exchange reached out to China Pharma Holdings this week after a string of unusual trading sessions for the company's common stock between July 10 and July 15. The pharmaceutical firm responded by distancing itself from the sudden market fluctuations, citing a lack of undisclosed corporate developments.
Comments (0)
No comments yet. Be the first!